An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2018
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- Sponsors Amgen
- 12 Sep 2018 Planned primary completion date changed from 15 Nov 2018 to 5 Nov 2018.
- 23 Aug 2018 Planned End Date changed from 31 May 2021 to 3 Jun 2021.
- 18 Jun 2018 Status changed from recruiting to active, no longer recruiting.